Mylan Dismissed From Massachusetts Multi-District AWP LitigationPITTSBURGH--(BUSINESS WIRE)--April 12, 2004--Mylan Laboratories Inc. (NYSE: MYL) announced that all claims pending against it in the consolidated, multi-district "Pharmaceutical Industry Average Wholesale Price Litigation" in the U.S. District Court for the District of Massachusetts have been dismissed.

Mylan was originally named as a defendant in four "AWP"-related lawsuits that were filed in California and later transferred to the court in Boston. Mylan filed a motion to dismiss all claims against it because none of the plaintiffs had identified any specific wrongdoing on Mylan's part. As Mylan's prior press releases indicated, on September 30, 2003, the court signed an order dismissing all claims against Mylan, but later rescinded that dismissal and gave the plaintiffs additional time to oppose Mylan's dismissal. During the time allotted, no plaintiff opposed Mylan's motion to dismiss. Each of the plaintiffs has now filed papers with the court voluntarily withdrawing their claims against Mylan.

Mylan Vice Chairman and CEO, Robert J. Coury said, "In October, when the judge rescinded the first dismissal, we said we were hopeful we would be in the same place once the scheduling issue was resolved. The scheduling has now worked itself out, the plaintiffs dropped their lawsuits against us and we have been formally dismissed from this litigation."

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc. that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.